간질 증상에 대한 바이오마커 표적 자극 (BTSEE)
간질에 대한 바이오마커 표적 자극의 안전성과 유효성
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: David Himes, BSEE
- 전화번호: 425-679-9505
- 이메일: dhimes@cadenceneuro.com
연구 장소
-
-
California
-
Palo Alto, California, 미국, 94304
- 모병
- Lucile Packard Children's Hospital Stanford
-
연락하다:
- Swetapadma Patnaik
- 전화번호: (650) 721-1458
- 이메일: sweta@stanford.edu
-
수석 연구원:
- Ann Hyslop Segeren, MD
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic
-
연락하다:
- Karla Crockett
- 전화번호: 507-538-9140
- 이메일: Crockett.Karla@mayo.edu
-
수석 연구원:
- Nicholas Gregg, MD
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Children's Medical Center
-
연락하다:
- Mariana Gallardo
- 전화번호: 682-303-4916
- 이메일: Mariana.Gallardo@cookchildrens.org
-
수석 연구원:
- M. Scott Perry, MD
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
수석 연구원:
- Hannah Goldstein, MD
-
연락하다:
- Deborah Grenard
- 전화번호: 206-987-8078
- 이메일: Cadence@seattlechildrens.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subject is greater than or equal to 7 years of age.
- Subject has focal onset seizures.
- Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
- Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
- Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
- For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
- Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
- A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
- Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
- Subject has had a brain MRI epilepsy evaluation within the past two years.
- Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.
Exclusion Criteria:
-
Subject has a history of substance abuse within the preceding two years.
-
Subject participated in another drug or device trial that may confound study results within the preceding 30 days.
-
Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.
-
Subject has anatomy that may interfere with electrode placement.
-
Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.
-
Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
-
Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.
-
Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
-
Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
-
Subject has primary generalized seizures.
-
Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
- The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
- Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
-
Subject, in the opinion of the Investigator, would be a poor study candidate.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 치료
|
Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adverse event rate
기간: Intervals through 7, 12, and 24 months post-implant
|
Determine adverse event rate, including adverse device effects and serious adverse events |
Intervals through 7, 12, and 24 months post-implant
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Seizure frequency
기간: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline. |
Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
|
Neurocognitive testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Depression testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Anxiety testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Quality of life testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Sleep testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Seizure severity testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Caregiver burden testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Suicidality risk testing
기간: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother. 2017 Jul;17(7):661-666. doi: 10.1080/14737175.2017.1331129. Epub 2017 May 25.
- Kerezoudis P, Grewal SS, Stead M, Lundstrom BN, Britton JW, Shin C, Cascino GD, Brinkmann BH, Worrell GA, Van Gompel JJ. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg. 2018 Aug;129(2):533-543. doi: 10.3171/2017.5.JNS163134. Epub 2017 Oct 20.
- Lundstrom BN, Gompel JV, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. Brain Commun. 2019;1(1):fcz010. doi: 10.1093/braincomms/fcz010. Epub 2019 Sep 6.
- Starnes K, Miller K, Wong-Kisiel L, Lundstrom BN. A Review of Neurostimulation for Epilepsy in Pediatrics. Brain Sci. 2019 Oct 18;9(10):283. doi: 10.3390/brainsci9100283.
- Alcala-Zermeno JL, Gregg NM, Van Gompel JJ, Stead M, Worrell GA, Lundstrom BN. Cortical and thalamic electrode implant followed by temporary continuous subthreshold stimulation yields long-term seizure freedom: A case report. Epilepsy Behav Rep. 2020 Sep 2;14:100390. doi: 10.1016/j.ebr.2020.100390. eCollection 2020.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CAD2004
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .